Technology News and Research

RSS

IMRT facilitates radiation dose escalation without compromising long-term morbidity for prostate cancer

In an analysis of three different types of radiation therapy used to treat localized prostate cancer, compared with conformal radiation therapy, intensity-modulated radiation therapy (IMRT) was associated with fewer diagnoses of gastrointestinal adverse effects, hip fractures, and receipt of additional cancer treatments but more erectile dysfunction, while proton therapy was associated with more gastrointestinal adverse effects than IMRT.

18 Apr 2012

FDA to regulate smartphone medical applications; Companies to enter $4 billion insurance exchange market

An onslaught of mobile health technology has forced an arranged marriage between smartphone app makers and the Food and Drug Administration -- because someone had to regulate them. There's just one problem: Many of the tech wizards aren't used to FDA supervision. And now, both sides are struggling to figure out how to live with each other.

18 Apr 2012

Engineered particles tied to penetratin discover, deliver ligands for mitochondria, ribosomes

Scientists who developed a technology for identifying and targeting unique protein receptor ZIP Codes on the cellular surface have found a way to penetrate the outer membrane and deliver engineered particles - called iPhage - to organelles inside the cell.

18 Apr 2012

Bruker introduces new products at Analytica 2012

At Analytica 2012, Bruker today announced several new product introductions for the research, industrial and applied markets, designed to deliver confident analyses with increased sensitivity, specificity and productivity, and to push the boundaries of advanced molecular and materials research applications.

18 Apr 2012

Medtronic plans IN.PACT Global drug-eluting balloon SFA clinical study

In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.

From Medtronic 18 Apr 2012

Allied Healthcare announces Coridon license to vector technology

Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.

17 Apr 2012

Innovation in healthcare without borders: An invaluable contribution of diagnostics

For the third year in a row, the European Diagnostic Manufacturers Association (EDMA) has been one of the strategic partners of the European Commission in organising the Innovation in Healthcare without Borders conference.

17 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

CSL Behring commits donations to World Federation of Hemophilia GAP program

To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year.

17 Apr 2012

First Edition: April 17, 2012

Today's health policy headlines include reports from the presidential campaign trail as well as news from the states regarding abortion laws.

17 Apr 2012

Novel system for 3D reconstruction and examination of tissues at microscopic resolution

Researchers have developed a novel, easy-to-use system for three-dimensional (3D) reconstruction and examination of tissues at microscopic resolution, with the potential to significantly enhance the study of normal and disease processes, particularly those involving structural changes. The new approach, using conventional histopathological methods, is described in the May issue of The American Journal of Pathology.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Study finds lower cytokine levels in the plasma of children with autism

A University of Kansas Medical Center study found significantly lower levels of several cytokines, the immune system's messengers and regulators, in the plasma of children with autism disorder (AD) compared to that of unrelated healthy siblings from other families who had members with autism spectrum disorders.

17 Apr 2012

U.S. should separate diplomatic pressures on N. Korea from humanitarian assistance, provide food aid

A Seattle Times editorial says a "radical response" to North Korea's rocket launch would be to "keep diplomatic channels open with the 240,000 tons of food aid planned before" the launch. "Providing food aid is wholly apart from maintaining political and economic pressure on the country," the editorial says, adding, "Sending food does not preclude international sanctions to deny North Korea access to electronic technology and military hardware."

17 Apr 2012

Brainlab announces first patient procedures with Curve Image Guided Surgery at UCSF

Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.

17 Apr 2012

International Microbicides Conference to discuss state of HIV prevention research

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

MTR can prevent cell death in patients with TBI

Wake Forest Baptist Medical Center researchers seeking a successful treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.

17 Apr 2012

T-FET biosensor can detect biomolecules at ultra-low concentrations

A new quantum mechanical-based biosensor designed by a team at University of California, Santa Barbara offers tremendous potential for detecting biomolecules at ultra-low concentrations, from instant point-of-care disease diagnostics, to detection of trace substances for forensics and security.

17 Apr 2012

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

17 Apr 2012

Technology News and Research

IMRT facilitates radiation dose escalation without compromising long-term morbidity for prostate cancer

FDA to regulate smartphone medical applications; Companies to enter $4 billion insurance exchange market

Engineered particles tied to penetratin discover, deliver ligands for mitochondria, ribosomes

Bruker introduces new products at Analytica 2012

Medtronic plans IN.PACT Global drug-eluting balloon SFA clinical study

Allied Healthcare announces Coridon license to vector technology

Innovation in healthcare without borders: An invaluable contribution of diagnostics

Imaxio closes EUR 2.9 million funding round

CSL Behring commits donations to World Federation of Hemophilia GAP program

First Edition: April 17, 2012

Novel system for 3D reconstruction and examination of tissues at microscopic resolution

ImmunoGen commences IMGN529 Phase I trial in NHL

Study finds lower cytokine levels in the plasma of children with autism

U.S. should separate diplomatic pressures on N. Korea from humanitarian assistance, provide food aid

Brainlab announces first patient procedures with Curve Image Guided Surgery at UCSF

International Microbicides Conference to discuss state of HIV prevention research

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

MTR can prevent cell death in patients with TBI

T-FET biosensor can detect biomolecules at ultra-low concentrations

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News